"Including
evidence-based decision-making in the healthcare coverage process would
ensure that use of new therapy and technology is tied to evidence of
clinical benefit, resulting in a value-based health care system."
Rita Redberg, MD. Health
Affairs,
February 2007 |
275
Middlefield Road
Suite 200
Menlo
Park, CA
94025
Tel:
650.327.2085
Toll-free: 877.571.3779
Fax:
650.327.1506
Email: info@cedarecon.com
|
Cedar
Associates LLC provides
life
sciences
organizations and companies with scientifically reliable and credible
evidence on clinical outcomes and economics of services and
technologies. We use state-of-the-art analytical techniques and seek to
present our findings in a manner that is readily understood by a
diverse audience, such as physicians, patients, managers, and
third-party payers and decision-makers.
We
have
close collaborations with numerous international renowned
experts at local, regional and national institutions (e.g., Stanford
University,
UC Berkeley,
California State University East Bay, Sutter
Health, Veterans’ Affairs Hospitals). These collaborations
not only
expand the scope of state-of-the-art expertise on projects, but
increase our capacity to readily staff projects.
Cost Effectiveness
|
 |
We
provide state-of-the-art
analyses of the economic implications of medical technologies
(pharmaceuticals, devices, and diagnostics) and services. Based on a
strong foundation in decision analyses, epidemiology, statistics, and
econometrics–combined
with more than a decade of experience working in and with life sciences
companies–we
generate analyses that are useful for a diverse array of stakeholders. |
Budget Impact
|
 |
Third-party
payers routinely
need and request high-quality evidence on
the potential fiscal implications of funding new and emerging health
technologies and services. We believe that such discussions should be
based on the foundation of "principled negotiations." Analyses to
inform these discussions require a
mutual understanding and agreement on diverse set of inputs. We have
extensive experience obtaining reliable information to such question
and developing credible fiscal forecasts. |
Strategy
|
 |
Cedar
Associates LLC assists
company decision makers–from
regulatory, clinical, commercial, and reimbursement teams–to
develop an effective strategy for commercializing a new product. Our
emphasis is primarily on the economic and reimbursement strategy, and
our experience reveals that it must be informed from input of other
teams. |
Evidence Synthesis
|
 |
We
conduct
systematic reviews
of medical literature according to the standards expected from major
stakeholders. Our staff retrieves pertinent publications and abstracts
from international congresses. We also rely on clinical and economic
experts to fill in potential gaps from using electronic databases. We
generate evidence reports that have been submitted for use in AMCP
dossiers and NICE submissions, and for reports to regulatory agencies,
clinical investigators, and senior managers. |
Statistics and
Econometric
Analysis
|
 |
Our
staff has
experience programming in SAS, STATA, S-Plus, Mathematica, and
R-statistical language. Our analyses have been published in
peer-reviewed journals, submitted to FDA, and submitted to
reimbursement agencies (CMS, UK NICE). We have experience with survival
models, ANOVA models, multivariate regression (Cox, GLM, GEE, fixed and
random effect models, logistic), time series, and Bayesian methods and
forecasting. |
|
 |
 |
 |
 |
PRESS
RELEASES
May 14,
2010
The Wall Street Journal
features an editorial by Dr. John Hornberger, addressing Dr. Mark
Thornton's op-ed (May 7) entitled "The FDA vs. Bone Cancer Patients".
The letter discusses effective sample size computation, and encourages
more consideration of proven, robust statistical methods in FDA
clinical trial evaluation. View
article (PDF also
available).
May
9, 2010
Cedar Associates LLC has been featured in the Silicon Valley / San Jose
Business Journal, a leading source of comprehensive business news and
in-depth analysis in the Bay Area. View article.
April
5, 2010
John Hornberger, MD, MS, has been accepted for membership to the
American Society of Clinical Oncology (ASCO). As membership to this
organization is exclusive to oncologists and oncology researchers, this
achievement recognizes Dr. Hornberger's accomplishments in--and
demonstrated commitment to--health economic research in the oncology
field.
November
3, 2009
A manuscript titled “Economic implications of 21-gene breast
cancer risk assay from the perspective of an Israeli managed healthcare
organization,” co-authored by John Hornberger, MD, MS and
Julie Doberne with Shmuel Klang, PhD has been accepted by Value In Health
for
publication. Read
more.
September
14, 2009
Economic evaluation of
R-CVP, written by Dr. Hornberger in collaboration with Carolina Reyes
(Genentech Inc.), Deborah Lubeck (ICON Clinical Research), and Nancy
Valente (Genentech Inc.), favorably reviewed by the NHS Centre for
Reviews and Dissemination (CRD). Read
more.
June
26, 2009
Policy analysis by John Hornberger, MD, MS, on American health care
reform was featured in the May/June 2009 issue of ISPOR connections. Read more.
May 5,
2009 Molecular Diagnostics
cites Cedar
Associate LLC's economic analysis of Genomic Health's Oncotype
DX as a "gold standard in
novel diagnostics economic analysis." Read
more.
April
23, 2009 JIAPAC
publishes Cedar manuscript coauthored by Ashwini Shewade, MS, John
Hornberger, MD, MS, and John Bartlett, MD, which proposes practical
solutions to barriers to antiretroviral treatment
in resource-limited settings. Read
more.
April 10, 2009 John
Hornberger, MD, MS, founder of Cedar, will be presenting
a session on Pharmaeconomics, Cost
Effectiveness, and Outcome Analysis for Personalized Medicine at the Drug
Information Association's 45th Annual Meeting. Read
more.
February 18, 2009
Poster coauthored by Cedar Associates Research Analyst, Julie Doberne,
on capsule endoscopy was accepted for presentation at Digestive Disease
Week. Read
more.
February 9, 2009 Cedar
presents report to Government Accounting Office (GAO) on the financial
implications of home hemodialysis. Read
more.
|
 |
 |
 |
 |
|
